if i start glp 1 can i stop GLP-1 nausea: How to handle GLP-1s' most common side effect How Long for GLP-1 to

Many doctors anticipate that the medication may be FDA approved sometime in 2027, Siegel says

Should retatrutide receive future regulatory approval, any UK prescribing would be subject to MHRA marketing authorisation, and access would likely be governed through the standard NICE technology appraisal process as is the case for existing obesity pharmacotherapies

Given the significant differences in mechanism, evidence, regulatory status, and clinical indication, a direct head-to-head comparison of retatrutide and tesamorelin as interchangeable options is not clinically appropriate

[18] [5] Rapid weight loss associated with this class of medication may increase the risk of gallbladder disease, including gallstones